ReviewJournal of ovarian research2026
Mendelian randomization in ovarian research: applications in PCOS, ovarian aging, and assisted reproductive technology.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian disorders such as polycystic ovary syndrome (PCOS) and primary ovarian insufficiency (POI) have complex etiologies that are difficult to disentangle using observational studies. Mendelian randomization (MR) offers a powerful approach to identify causal drivers of these conditions, with direct implications for assisted reproductive technology (ART), but its application is blocked by the ART phenotype gap, namely the absence of large-scale GWAS for cycle-specific outcomes. This review synthesizes a conceptual framework to navigate this gap. In the near term, researchers can use existing genetic data through two complementary strategies, upstream exposure analysis and proxy outcome analysis, both requiring rigorous validation and sensitivity testing. In the long term, the field must build deeply phenotyped ART genomic consortia with standardized data and ethical governance. This approach enables causal hypothesis generation using existing data, while recognizing that definitive evidence will require deeply phenotyped consortia in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.